Physician profile
Frank J Eidelman
NPI 1235199969
$57,157.75
in general payments reported to CMS, 2019-2025
15 companies · $865 in 2025
The $865 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $6,792 · 2021: $21K · 2023: $228 · 2024: $472 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,565.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19,680.44 | 2019 | |
| Glaxosmithkline, LLC. | $18,911.45 | 2020-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $9,734.22 | 2021-2025 | Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $7,706.95 | 2019-2025 | |
| Ionis Pharmaceuticals, INC. | $268.29 | 2025 | Dawnzera |
| Galderma Laboratories, L.P. | $156.94 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $118.75 | 2023 | Ayvakit |
| Genentech, INC. | $114.00 | 2019 | |
| Intuitive Surgical, INC. | $109.66 | 2023 | Da Vinci Surgical System |
| Grifols Shared Services North America, INC. | $94.43 | 2024 | Xembify |
| Biocryst US Sales Co., LLC | $93.96 | 2025 | Orladeyo |
| Regeneron Healthcare Solutions, INC. | $78.14 | 2019 | |
| Alk-Abello, INC | $65.00 | 2021 | |
| Novo Nordisk INC | $13.68 | 2020 | |
| Pfizer INC. | $11.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Eidelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.